Eledon Pharmaceuticals To Present At The Cantor Global Healthcare Conference
Date
9/11/2024 4:16:13 PM
(MENAFN- GlobeNewsWire - Nasdaq) IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare conference on Wednesday, September 18, 2024, at 8:35 a.m. ET.
To register in advance for the fireside chat webcast, sign up here .
A webcast replay will be accessible following the live session on the Company's website under Events .
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company's website at .
Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
...
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253 8881
...
Source: Eledon Pharmaceuticals
MENAFN11092024004107003653ID1108663943
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.